title: Homocysteine: update on a new risk factor.
abstract: A high fasting plasma homocysteine level is an independent risk factor for atherosclerosis and venous thrombosis. Vitamin therapy can lower homocysteine levels, but no benefit has yet been demonstrated; studies using clinical outcomes as endpoints are now in progress.
authors.affiliation: Department of Cardiology, Cleveland Clinic, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: Ballal
authors.forename: D W
authors.initials: DW
authors.lastname: Jacobsen
authors.forename: K
authors.initials: K
authors.lastname: Robinson
mesh_terms: D001161:Arteriosclerosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D005492:Folic Acid / Q000627:therapeutic use; D006710:Homocysteine / Q000096:biosynthesis / Q000097:blood*; D006801:Humans; D011379:Prognosis; D011736:Pyridoxine / Q000627:therapeutic use; D012307:Risk Factors; D013924:Thrombophlebitis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D014805:Vitamin B 12 / Q000627:therapeutic use
chemical_list: D006710:Homocysteine; D005492:Folic Acid; D011736:Pyridoxine; D014805:Vitamin B 12